Inhibition of Nitric Oxide Production in Clinical Septic Shock

  • E. D. Bennett
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 24)


There is now an increasing body of evidence which strongly suggests that excess production of nitric oxide (NO) is responsible for the severe hypotension commonly seen in septic shock. Very recently, Gomez-Jimenez et al. [1] have shown that plasma nitrite and nitrate levels were not different between a control group of patients and those with sepsis, but the values in both these groups were significantly lower than in a group of patients with septic shock. In addition, they were able to show a correlation between nitrite and nitrate levels and cardiac output and plasma endotoxin levels in the septic group.


Nitric Oxide Cardiac Output Septic Shock Methylene Blue Pulmonary Vascular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gómez-Jiménez J, Salgado A, Mourelle M, et al (1995) L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 23:253–258PubMedCrossRefGoogle Scholar
  2. 2.
    Cobb JP, Cunnion RE, Danner RL (1993) Nitric oxide as a target for therapy in septic shock. Crit Care Med 21:1261–1263PubMedCrossRefGoogle Scholar
  3. 3.
    Cobb JP, Natanson C, Hoffman WD, et al (1992) N-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality in canines challenged with endotoxin. J Exp Med 176:1175–1182PubMedCrossRefGoogle Scholar
  4. 4.
    Biliar TR, Curran RD, Harbrecht BG, et al (1990) Modulation of nitrogen oxide synthesis in vivo: N mono-methyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol 48:565–569Google Scholar
  5. 5.
    Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibition on hypotension in patients with septic shock. Lancet 338:1557–1558PubMedCrossRefGoogle Scholar
  6. 6.
    Lorente JA, Landín L, De Pablo R, et al (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21:1287–1285PubMedCrossRefGoogle Scholar
  7. 7.
    Petros A, Lamb, Leone A, et al (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34–39PubMedCrossRefGoogle Scholar
  8. 8.
    Preiser JC, Lejeune P, Roman A, et al (1995) Methylene blue administration in septic shock: A clinical trial. Crit Care Med 23:259–264PubMedCrossRefGoogle Scholar
  9. 9.
    Brüssel T, Meyer J (1995) Nitric oxide synthesis inhibition in septic shock. Crit Care Med 23:412 (Letter)PubMedCrossRefGoogle Scholar
  10. 10.
    Cobb JP, Cunnion RE, Danner RL (1995) Nitric oxide synthesis inhibition in septic shock. Crit Care Med 23:413–414 (Letter)CrossRefGoogle Scholar
  11. 11.
    Lorente J A Landin, Renes E, Liste D (1995) Nitric oxide synthesis inhibition in septic shock. Crit Care Med 23:414–415 (Letter)CrossRefGoogle Scholar
  12. 12.
    Yu M, Tomasa G (1993) A double blind, prospective, randomized trial ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of adult respiratory distress syndrome. Crit Care Med 21:1635–1642PubMedCrossRefGoogle Scholar
  13. 13.
    Bogle RG, Whitley GS, Soo SC, et al (1994) Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol 111: 1257–1261PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • E. D. Bennett

There are no affiliations available

Personalised recommendations